First Brands Group debt targeted by Apollo Global Management - report
GAITHERSBURG, Md. - Elutia Inc. (NASDAQ:ELUT), a small-cap medical device company with a market capitalization of $83.5 million, has been selected to exhibit its EluPro Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange taking place September 17 in Las Vegas, the company announced Thursday. According to InvestingPro data, analysts maintain a Strong Buy rating on the stock despite recent market challenges.
The EluPro device is the first and only FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices and neurostimulators. The product combines a natural biologic scaffold with antibiotics that release over time, aiming to promote tissue regeneration while providing antimicrobial protection at the surgical site. With annual revenue of $23.7 million, Elutia faces some financial headwinds, as InvestingPro analysis reveals concerns about cash burn rates and short-term obligations.
Vizient, described as the nation’s largest provider-driven healthcare performance improvement company, hosts the annual exchange to allow selected suppliers to demonstrate their products to hospital supply chain and clinical leaders.
"EluPro is a prime example of how innovation can transform patient care by addressing critical post-surgical complications like infection, migration, and erosion," said Dr. Kimberly Mulligan, GM and VP of Elutia’s Cardiovascular Division, in the press release statement.
The Vizient Innovative Technology Program has reviewed over 1,700 product submissions since 2003. The exchange offers healthcare providers an opportunity to interact with products that could impact clinical care or business models.
Elutia develops drug-eluting biomatrix products designed to improve compatibility between medical devices and patients. The company focuses on technologies for patients requiring implantable devices. While the stock has experienced a challenging week with a 14.6% decline, InvestingPro subscribers have access to 6 additional key insights and detailed financial metrics to better evaluate the company’s potential.
In other recent news, Aleutia reported its Q2 2025 earnings, which showed a mixed performance. The company posted a loss per share of $0.26, which did not meet the forecasted loss of $0.19 per share. Revenue for the quarter was $6.3 million, falling short of the expected $7.8 million. Despite these results, Aleutia emphasized strong growth in specific segments and strategic initiatives. Additionally, analysts have been closely monitoring the company’s developments, but no upgrades or downgrades were mentioned in recent reports. These recent developments highlight the challenges Aleutia faces in meeting market expectations. Investors may find interest in how the company plans to leverage its growth areas moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.